| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8568793 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Dec, 2031
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687506 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Feb, 2030
(6 years from now) | |
Sodium Nitrite is owned by Hope Pharms.
Sodium Nitrite contains Sodium Nitrite.
Sodium Nitrite has a total of 2 drug patents out of which 0 drug patents have expired.
Sodium Nitrite was authorised for market use on 14 February, 2012.
Sodium Nitrite is available in solution;intravenous dosage forms.
Sodium Nitrite can be used as sodium nitrite injection is administered by intravenous injection; sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning.
The generics of Sodium Nitrite are possible to be released after 24 December, 2031.
Drugs and Companies using SODIUM NITRITE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Sodium nitrite injection is administered by intravenous injection; Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning
Dosage: SOLUTION;INTRAVENOUS
SODIUM NITRITE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic